Home > Healthcare > Medical Devices > Medical Supplies > MRI Contrast Media Market

MRI Contrast Media Market Trends

Report ID: GMI7600
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

MRI Contrast Media Market Trends

The continual advancement with collaborative research for effective therapies and precise diagnostic results expect to explore opportunities in the market. For instance, in June 2023, a recent partnership between Philips and Polarean integrates multi-nuclei imaging from Philips’ 3T MR 7700 MRI system with Xenoview, a hyperpolarized Xenon-based MRI contrast agent. This collaboration enhances lung imaging detail and improves accuracy in measuring lung ventilation.
Similarly, contrast media possess the capability to track the developments in brain, liver, or breast tumors, offering enhanced guidance in surgical interventions. With the expanding applications of MRI, procedures utilizing these contrast media are expected to rise. Therefore, the market is anticipated to grow in the coming years due to escalating healthcare spending, a surge in chronic diseases, research funding, collaborations, acquisitions, and increased public awareness.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The hospitals segment is anticipated to record over 4.5% CAGR from 2023 to 2032 as these are primary facilities for patients undergoing major diagnostic tests, making MRI contrast media the focal point.

The extracellular contrast agents segment is expected to reach USD 1.9 billion by 2032 due to their efficacy in enhancing image contrast.

Bayer HealthCare LLC, Guerbet LLC, GE HealthCare, Lantheus Medical Imaging, Inc., B. Chemicals and Pharmaceuticals Ltd., Bracco, BioPAL, Inc., Vitalquan, LLC, Fresenius Kabi, and Polarean.